Bristol Myers Squibb (BMS) has announced a collaboration with Microsoft to enhance early detection and equitable access to lung cancer care through AI-driven workflows using Microsoft’s Precision Imaging Network. This initiative aims to deploy FDA-cleared radiology AI algorithms that can analyze medical imaging like X-rays and CT scans to identify lung disease, including hard-to-detect lung nodules associated with Non-Small Cell Lung Cancer (NSCLC). With lung cancer being the leading cause of cancer deaths in the U.S., the partnership seeks to address health disparities, particularly in medically underserved communities. The integrated AI platform is expected to improve operational efficiency and patient outcomes while facilitating better follow-up for patients with incidental findings. Both companies emphasize their commitment to health equity and utilizing technology to improve patient care.
Tue, 20 Jan 2026 12:01:14 GMT | The AI Journal